Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Brousset

Showing results (131-140 of 148) with videos related to

Pageof 15
Sort By:
Biomarker Research|December 13, 2019
Immune biomarkers in thymic epithelial tumors: expression patterns, prognostic value and comparison of diagnostic tests for PD-L1Isabelle Rouquette, Estelle Taranchon-Clermont, Julia Gilhodes, et al.
Virchows Archiv : an International Journal of Pathology|October 13, 2025
FOS gene fusions in osteosarcoma raise the hypothesis of malignant transformation of osteoblastomaChristophe Bontoux, Marie Csanyi-Bastien, Corinne Bouvier, et al.
The American Journal of Surgical Pathology|August 2, 2021
High-grade Follicular Lymphomas Exhibit Clinicopathologic, Cytogenetic, and Molecular Diversity Extending Beyond Grades 3A and 3BCamille Laurent, José Adélaïde, Arnaud Guille, et al.
The Journal of Experimental Medicine|October 22, 2008
Myeloid cell differentiation arrest by miR-125b-1 in myelodysplastic syndrome and acute myeloid leukemia with the t(2;11)(p21;q23) translocationMarina Bousquet, Cathy Quelen, Roberto Rosati, et al.
Nature Communications|January 25, 2020
Resistance of melanoma to immune checkpoint inhibitors is overcome by targeting the sphingosine kinase-1Caroline Imbert, Anne Montfort, Marine Fraisse, et al.
Haematologica|November 8, 2011
In situ mantle cell lymphoma: clinical implications of an incidental finding with indolent clinical behaviorAlejandra Carvajal-Cuenca, Luz F Sua, Nhora M Silva, et al.
Blood|February 26, 2026
Patient-Derived Lymphoma Spheroids Reveal Predictive Markers of Glofitamab Resistance in Relapsed/Refractory B-NHLPaul Marcoux, Fabien Gava, Marie Tosolini, et al.
Cancers|January 27, 2021
Characterization of Macrophages and Osteoclasts in the Osteosarcoma Tumor Microenvironment at Diagnosis: New Perspective for Osteosarcoma Treatment?Anne Gomez-Brouchet, Julia Gilhodes, Nathalie Van Acker, et al.
Blood|February 18, 2010
Wide diversity of PAX5 alterations in B-ALL: a Groupe Francophone de Cytogenetique Hematologique studyEtienne Coyaud, Stephanie Struski, Nais Prade, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 7, 2017
A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell LymphomaMyron S Czuczman, Marek Trněný, Andrew Davies, et al.
Pageof 15

Showing results (131-140 of 148) with videos related to

Sort By:
Pageof 15
Biomarker Research|December 13, 2019
Immune biomarkers in thymic epithelial tumors: expression patterns, prognostic value and comparison of diagnostic tests for PD-L1Isabelle Rouquette, Estelle Taranchon-Clermont, Julia Gilhodes, et al.
Virchows Archiv : an International Journal of Pathology|October 13, 2025
FOS gene fusions in osteosarcoma raise the hypothesis of malignant transformation of osteoblastomaChristophe Bontoux, Marie Csanyi-Bastien, Corinne Bouvier, et al.
The American Journal of Surgical Pathology|August 2, 2021
High-grade Follicular Lymphomas Exhibit Clinicopathologic, Cytogenetic, and Molecular Diversity Extending Beyond Grades 3A and 3BCamille Laurent, José Adélaïde, Arnaud Guille, et al.
The Journal of Experimental Medicine|October 22, 2008
Myeloid cell differentiation arrest by miR-125b-1 in myelodysplastic syndrome and acute myeloid leukemia with the t(2;11)(p21;q23) translocationMarina Bousquet, Cathy Quelen, Roberto Rosati, et al.
Nature Communications|January 25, 2020
Resistance of melanoma to immune checkpoint inhibitors is overcome by targeting the sphingosine kinase-1Caroline Imbert, Anne Montfort, Marine Fraisse, et al.
Haematologica|November 8, 2011
In situ mantle cell lymphoma: clinical implications of an incidental finding with indolent clinical behaviorAlejandra Carvajal-Cuenca, Luz F Sua, Nhora M Silva, et al.
Blood|February 26, 2026
Patient-Derived Lymphoma Spheroids Reveal Predictive Markers of Glofitamab Resistance in Relapsed/Refractory B-NHLPaul Marcoux, Fabien Gava, Marie Tosolini, et al.
Cancers|January 27, 2021
Characterization of Macrophages and Osteoclasts in the Osteosarcoma Tumor Microenvironment at Diagnosis: New Perspective for Osteosarcoma Treatment?Anne Gomez-Brouchet, Julia Gilhodes, Nathalie Van Acker, et al.
Blood|February 18, 2010
Wide diversity of PAX5 alterations in B-ALL: a Groupe Francophone de Cytogenetique Hematologique studyEtienne Coyaud, Stephanie Struski, Nais Prade, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 7, 2017
A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell LymphomaMyron S Czuczman, Marek Trněný, Andrew Davies, et al.
Pageof 15